These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33588315)

  • 21. [Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic].
    Eliseeva DD; Vasiliev AV; Abramova AA; Kochergin IA; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7. Vyp. 2):31-36. PubMed ID: 34387443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab in Covid era.
    Iovino A; Olivieri N; Aruta F; Giaquinto E; Ruggiero L; Spina E; Tozza S; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2021 Jun; 51():102908. PubMed ID: 33812222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
    J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The COVID-19 pandemic and the use of MS disease-modifying therapies.
    Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
    Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
    [No Abstract]   [Full Text] [Related]  

  • 26. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
    Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
    Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
    J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Laroni A; Schiavetti I; Sormani MP; Uccelli A
    Mult Scler; 2021 Dec; 27(14):2126-2136. PubMed ID: 33205695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronavirus disease 2019 in Latin American patients with multiple sclerosis.
    Fragoso YD; Schiavetti I; Carmisciano L; Ponzano M; Steinberg J; Treviño-Frenk I; Ciampi E; Vecino MCA; Correa EP; Carcamo C; Gomes S; Pimentel MLV; Santos GAC; Vrech C; Winckler TCA; Sormani MP
    Mult Scler Relat Disord; 2021 Oct; 55():103173. PubMed ID: 34332462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Guevara C; Villa E; Rosas CS; Diaz V; Naves R
    Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19.
    Adamczyk B; Morawiec N; Arendarczyk M; Baran M; Wierzbicki K; Sowa P; Adamczyk-Sowa M
    Neurol Neurochir Pol; 2021; 55(4):357-368. PubMed ID: 34346052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 will change MS care forever - No.
    Preziosa P; Rocca MA; Filippi M
    Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
    [No Abstract]   [Full Text] [Related]  

  • 35. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?
    Mycko MP
    Neurol Neurochir Pol; 2020; 54(6):490-501. PubMed ID: 33073348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Citywide Approach to SARS-CoV2 Testing.
    Broach JP; Lowell M; Brown O; Martin C; Muller M; Shirshac J; Perrone D; Smith W; Castiel M; Kobayashi KJ; Lapriore CM; Dickson EW; Babu KM
    Front Public Health; 2021; 9():695442. PubMed ID: 34277553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Practical management of the patients with hematological diseases during the COVID-19 pandemic in Japan].
    Hagihara M; Ohara S; Uchida T; Inoue M
    Rinsho Ketsueki; 2021; 62(2):115-124. PubMed ID: 33678770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.
    Komoni E; Jashari F; Boshnjaku D; Myftiu B; Pushka M; Blyta A; Nallbani-Komoni R
    Med Sci Monit; 2024 Jan; 30():e942992. PubMed ID: 38287659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature.
    Saraceno L; Susani EL; Marazzi MR; Moioli MC; Agostoni EC; Protti A
    Neurol Sci; 2021 Dec; 42(12):4881-4884. PubMed ID: 34431013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.